CIK 0001719714 · Non-accelerated filer<br>Smaller reporting company
Mereo BioPharma Group plc
Sign in to watch- Ticker
- MREO
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- United Kingdom
- Entity type
- operating
- Phone
- 4403330237300
- Business address
- ONE CAVENDISH PLACE, FOURTH FLOOR, LONDON, United Kingdom, W1G 0QF
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-08-22 | PAKIANATHAN DEEPIKA Director | Option exercise | +2,071 | $3.87 | $8K | 105,244 |
| 2024-08-22 | PAKIANATHAN DEEPIKA Director | Sale | −105,244 | $4.43 | $466K | 0 |
| 2024-08-22 | PAKIANATHAN DEEPIKA Director | Option exercise · Share Options (right to buy) | −5,500 | 0 | ||
| 2024-08-22 | PAKIANATHAN DEEPIKA Director | Option exercise · Share Options (right to buy) | −11,000 | 0 | ||
| 2024-08-22 | PAKIANATHAN DEEPIKA Director | Option exercise · Share Options (right to buy) | −31,500 | 0 | ||
| 2024-08-22 | PAKIANATHAN DEEPIKA Director | Option exercise · Share Options (right to buy) | −55,000 | 0 | ||
| 2024-08-22 | PAKIANATHAN DEEPIKA Director | Option exercise · Share Options (right to buy) | −55,000 | 0 | ||
| 2024-08-22 | PAKIANATHAN DEEPIKA Director | Option exercise · Share Options (right to buy) | −15,000 | 30,000 | ||
| 2024-06-26 | Sermon Charles General Counsel | Sale | −32,187 | $3.39 | $109K | 184,387 |
| 2024-06-26 | Lewicki John A. Chief Scientific Officer | Sale | −16,808 | $3.39 | $57K | 48,779 |
| 2024-06-26 | Fox Christine Ann Chief Financial Officer | Sale | −29,439 | $3.39 | $100K | 57,571 |
| 2024-06-26 | Scots-Knight Denise Chief Executive Officer | Sale | −92,273 | $3.39 | $313K | 709,518 |
| 2024-06-26 | Hughes-Wilson Alexandra See Remarks | Sale | −22,968 | $3.39 | $78K | 34,548 |
| 2024-06-25 | Sermon Charles General Counsel | Sale | −14,202 | $3.69 | $52K | 216,574 |
| 2024-06-25 | Lewicki John A. Chief Scientific Officer | Sale | −7,416 | $3.69 | $27K | 65,587 |
| 2024-06-25 | Fox Christine Ann Chief Financial Officer | Sale | −12,990 | $3.69 | $48K | 87,010 |
| 2024-06-25 | Scots-Knight Denise Chief Executive Officer | Sale | −40,712 | $3.69 | $150K | 801,791 |
| 2024-06-25 | Hughes-Wilson Alexandra See Remarks | Sale | −10,134 | $3.69 | $37K | 57,516 |
| 2024-06-21 | Lewicki John A. Chief Scientific Officer | Option exercise | +69,000 | 73,003 | ||
| 2024-06-21 | Lewicki John A. Chief Scientific Officer | Option exercise · Performance Based Restricted Stock Unit | +69,000 | 46,000 |
Page 5 of 7 · 139 trades